206 related articles for article (PubMed ID: 35237300)
21. Identification of HCG18 and MCM3AP-AS1 That Associate With Bone Metastasis, Poor Prognosis and Increased Abundance of M2 Macrophage Infiltration in Prostate Cancer.
Chen Y; Chen Z; Mo J; Pang M; Chen Z; Feng F; Xie P; Yang B
Technol Cancer Res Treat; 2021; 20():1533033821990064. PubMed ID: 33596783
[TBL] [Abstract][Full Text] [Related]
22. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
Xue B; Li S; Jin X; Liu L
BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Analysis of lncRNA-Mediated ceRNA Crosstalk and Identification of Prognostic Biomarkers in Wilms' Tumor.
Zheng H; Li BH; Liu C; Jia L; Liu FT
Biomed Res Int; 2020; 2020():4951692. PubMed ID: 32149111
[TBL] [Abstract][Full Text] [Related]
24. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
25. Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer.
Xiao R; Yang M; Tan Y; Ding R; Li D
Comput Math Methods Med; 2021; 2021():6676692. PubMed ID: 33727952
[TBL] [Abstract][Full Text] [Related]
26. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
27. Long Non-coding RNA
Chen J; Li X; Yang L; Zhang J
Front Cell Dev Biol; 2020; 8():625730. PubMed ID: 33614632
[TBL] [Abstract][Full Text] [Related]
28. Role of a Pyroptosis-Related lncRNA Signature in Risk Stratification and Immunotherapy of Ovarian Cancer.
Zhang Z; Xu Z; Yan Y
Front Med (Lausanne); 2021; 8():793515. PubMed ID: 35096881
[No Abstract] [Full Text] [Related]
29. ANGPTL4 regulates ovarian cancer progression by activating the ERK1/2 pathway.
Xu J; Wu F; Zhu Y; Wu T; Cao T; Gao W; Liu M; Qian W; Feng G; Xi X; Hou S
Cancer Cell Int; 2024 Feb; 24(1):54. PubMed ID: 38311733
[TBL] [Abstract][Full Text] [Related]
30. Prediction Model for Therapeutic Responses in Ovarian Cancer Patients Using Paclitaxel-Resistant Immune-Related lncRNAs.
Li X; Liu H; Wang F; Yuan J; Guan W; Xu G
Curr Med Chem; 2024 Feb; ():. PubMed ID: 38357948
[TBL] [Abstract][Full Text] [Related]
31. PDP1 Promotes Cell Malignant Behavior and Is Associated with Worse Clinical Features in Ovarian Cancer Patients: Evidence from Bioinformatics and In Vitro Level.
Song Y; Zhang J; Zhang L; Zhang S; Shen C
Comput Math Methods Med; 2022; 2022():7397250. PubMed ID: 36276992
[TBL] [Abstract][Full Text] [Related]
32. SSTR5‑AS1 functions as a ceRNA to regulate CA2 by sponging miR‑15b‑5p for the development and prognosis of HBV‑related hepatocellular carcinoma.
Xu J; Zhang J; Shan F; Wen J; Wang Y
Mol Med Rep; 2019 Dec; 20(6):5021-5031. PubMed ID: 31638225
[TBL] [Abstract][Full Text] [Related]
33. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
34. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
[TBL] [Abstract][Full Text] [Related]
35. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
36. Identification of latent biomarkers in connection with progression and prognosis in oral cancer by comprehensive bioinformatics analysis.
Reyimu A; Chen Y; Song X; Zhou W; Dai J; Jiang F
World J Surg Oncol; 2021 Aug; 19(1):240. PubMed ID: 34384424
[TBL] [Abstract][Full Text] [Related]
37. Modeling of senescence-related chemoresistance in ovarian cancer using data analysis and patient-derived organoids.
Cai X; Li Y; Zheng J; Liu L; Jiao Z; Lin J; Jiang S; Lin X; Sun Y
Front Oncol; 2023; 13():1291559. PubMed ID: 38370348
[TBL] [Abstract][Full Text] [Related]
38. Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer.
Zhang W; Ling Y; Li Z; Peng X; Ren Y
Cancer Med; 2023 Apr; 12(8):10045-10061. PubMed ID: 36645174
[TBL] [Abstract][Full Text] [Related]
39. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
40. Identification of lncRNA-miRNA-mRNA regulatory network associated with epithelial ovarian cancer cisplatin-resistant.
Zhao X; Tang DY; Zuo X; Zhang TD; Wang C
J Cell Physiol; 2019 Nov; 234(11):19886-19894. PubMed ID: 30950060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
